Beta1 integrins are distributed in adhesion structures with fibronectin and caveolin and in coated pits.
Integrins are found in adhesion structures, which link the extracellular matrix to cytoskeletal proteins. Here, we attempt to further define the distribution of beta1 integrins in the context of their association with matrix proteins and other cell surface molecules relevant to the endocytic process. We find that beta1 integrins colocalize with fibronectin in fibrillar adhesion structures. A fraction of caveolin is also organized along these adhesion structures. The extracellular matrix protein laminin is not concentrated in these structures. The alpha4beta1 integrin exhibits a distinct distribution from other beta1 integrins after cells have adhered for 1 h to extracellular matrix proteins but is localized in adhesion structures after 24 h of adhesion. There are differences between the fibronectin receptors: alpha5beta1 integrins colocalize with adaptor protein-2 in coated pits, while alpha4beta1 integrins do not. This parallels our earlier observation that of the two laminin receptors, alpha1beta1 and alpha6beta1, only alpha1beta1 integrins colocalize with adaptor protein-2 in coated pits. Calcium chelation or inhibition of mitogen-activated protein kinase kinase, protein kinase C, or src did not affect localization of alpha1beta1 and alpha5beta1 integrins in coated pits. Likewise, the integrity of coated-pit structures or adhesion structures is not required for integrin and adaptor protein-2 colocalization. This suggests a robust and possibly constitutive interaction between these integrins and coated pits.
Boyd
Nikhat D
ND
Department of Biochemistry, The University of Western Ontario, London, Canada.
Chan
Bosco M C
BM
Petersen
Nils O
NO
D033962:Adaptor Protein Complex 2 / Q000032:analysis / Q000378:metabolism; D021941:Caveolae / Q000378:metabolism; D051242:Caveolin 1; D022461:Caveolins / Q000032:analysis / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D002746:Chlorpromazine / Q000494:pharmacology; D003034:Coated Pits, Cell-Membrane / Q000737:chemistry / Q000378:metabolism*; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004705:Endocytosis / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000378:metabolism / Q000494:pharmacology; D005353:Fibronectins / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006982:Hypertonic Solutions / Q000494:pharmacology; D007150:Immunohistochemistry; D039222:Integrin alpha1beta1 / Q000032:analysis / Q000378:metabolism; D039041:Integrin alpha4beta1 / Q000032:analysis / Q000378:metabolism; D039081:Integrin alpha5beta1 / Q000032:analysis / Q000378:metabolism; D039121:Integrin alpha6beta1 / Q000032:analysis / Q000378:metabolism; D019012:Integrin beta1 / Q000032:analysis / Q000378:metabolism*; D007797:Laminin / Q000378:metabolism / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D011107:Polylysine / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology
C412373:AG 1879; D033962:Adaptor Protein Complex 2; C495540:CAV1 protein, human; D051242:Caveolin 1; D022461:Caveolins; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D005419:Flavonoids; D006982:Hypertonic Solutions; D039222:Integrin alpha1beta1; D039041:Integrin alpha4beta1; D039081:Integrin alpha5beta1; D039121:Integrin alpha6beta1; D019012:Integrin beta1; D007797:Laminin; D011743:Pyrimidines; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D011107:Polylysine; D004533:Egtazic Acid; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D002746:Chlorpromazine